Atty. Docket No: 21511/90135



## Application Serial No: 09/040,485

Sheet 1 of \_\_1

## U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE TRADE

INFORMATION DISCLOSURE STATEMENT

SERIAL No. 09/040,485

APPLICANT Dr. James A. Radosevich

ATTY. DOCKET NO. 21511/90135

FILING DATE March 17, 1998

**GROUP 1642** 

Examiner		Document Number	Date	Name	Class	Subclass	Filing Date
Examiner Initial							Filing Date if Appropriate
	_ AA					<del> </del>	-
	AB	<u> </u>				-	
-	AC						<u> </u>
	AD			<del></del>			
	AE		<del> </del>			<u> </u>	
	AF						
	AG					-	
	AH		<del>                                     </del>				
	AJ				+		
	AK					-	
•	] AN	<u> </u>	EODEIC	SN PATENT DOCUMEN	ITE	<u> </u>	<u> </u>
·	T	Document Number	Date	Country	Class	Subclass	Translation
	ļ	Document Number	Date	Country	Ciass	Subciass	Translation Yes No
	AL	-					_
	AM						
	AN						
	AO						
	_ AP		<u> </u>		<u>l</u>		
	<del></del>			luding Author, Title, Date	e, Pertinent Pages, Etc	.)	·
	AR	Information Disclosure Statement (March 8, 1999)					
	AS	KORIOTH, F. et al. (1994) "Cloning and Characterization of the Human Gene Encoding Aspartylbeta-Hydroxylase" Gene (2):395-399					
	AT	RADOSEVICH, J. A. et al. (1993) "Molecular - Cloning Protein Labyrinthin: V. Adenocarcinoma Tumor-Associated Antigen Detected by the Monoclonal Antibody- 44-3A6" Clin. Research 41(3):697-8					
-	AU	RADOSEVICH, J.A. et al. (1996) "Epitope Mapping of the Adenocarcinoma Related Monoclonal Antibody 44-3A6 on Labyrinthin" <i>Tumor Biol.</i> 21(1):14-15					
	AV	RADOSEVICH, J.A et al. (1997) "Anti-Sense Expression of Labyrinthin in A549 Cells Results In Contact Inhibition and Reduced Growth Rate" Tumor Biol. 18(1): 12					
	AW						
	AX Not entered 7/19/0						7/19/00
	AY						<del></del>
Examiner					Date Cor	sidered	